June 27, 2017 | Mitoconix Bio, a budding Israeli biopharmaceutical startup focused on therapies for neurological diseases, has secured $20 million in a Series A funding round led by Remiges Ventures. Founded in 2016 at the FutuRx biotechnology incubator, Mitoconix Bio has developed a unique method of slowing neuro-degenerative diseases using drugs which improve mitochondrial functioning. The company has an exclusive license for the technology behind its lead drug, which was developed by founder Daria Mochly-Rosen at Stanford University. The funding will be used to advance Mitoconix’s treatment of Huntington’s disease.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments